The “cancer immunogram”
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Visualizing the state of cancer–immune system interactions may spur personalized therapy
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“markers of response to cancer therapy have continued to evolve and now include factors well beyond established tumor-centric markers”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Blank et al., 2016
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Cited by
Items 101–200 of 748
Personalized neoantigen vaccines: A new approach to cancer immunotherapy
Aldous, A. R., & Dong, J. Z. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.021 · Cited by 128
Ottenhof, S. R., Djajadiningrat, R. S., Thygesen, H. H., Jakobs, P., Jóźwiak, K., Heeren, A. M., de Jong, J., Sanders, J., Horenblas, S., & Jordanova, E. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01253 · Cited by 131
Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
Drakes, M. L., & Stiff, P. J. (2018) · Cancers · doi:10.3390/cancers10090302 · Cited by 119
Li, B., Wang, Z., Wu, H., Xue, M., Lin, P., Wang, S., Lin, N., Huang, X., Pan, W., Liu, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3801 · Cited by 114
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 126
Dobosz, P., Stępień, M., Golke, A., & Dzieciątkowski, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052847 · Cited by 131
Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches
Song, D., Powles, T. B., Shi, L., Zhang, L., Ingersoll, M. A., & Lu, Y. (2019) · The Journal of Pathology · doi:10.1002/path.5306 · Cited by 116
Combining radiotherapy with immunotherapy: the past, the present and the future
Limbergen, E. J. V., Ruysscher, D. D., Pimentel, V. O., Marcus, D., Berbée, M., Hoeben, A., Rekers, N. H., Theys, J., Yaromina, A., Dubois, L. J., et al. (2017) · British Journal of Radiology · doi:10.1259/bjr.20170157 · Cited by 107
Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer
Aussy, A., Boyer, O., & Cordel, N. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00992 · Cited by 115
Phillips, D., Schürch, C. M., Khodadoust, M. S., Kim, Y. H., Nolan, G. P., & Jiang, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687673 · Cited by 104
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
van der Vlist, M., Kuball, J. H. E., Radstake, T. R. D. J., & Meyaard, L. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.131 · Cited by 118
Nadal, E., Massutí, B., Dómine, M., García‐Campelo, R., Cobo, M., & Felip, E. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02310-2 · Cited by 114
Adoptive T cell therapy: An overview of obstacles and opportunities
Baruch, E. N., Berg, A. L., Besser, M. J., Schachter, J., & Markel, G. (2017) · Cancer · doi:10.1002/cncr.30491 · Cited by 118
Impact of high tumor mutational burden in solid tumors and challenges for biomarker application
McNamara, M. G., Jacobs, T., Lamarca, Á., Hubner, R. A., Valle, J. W., & Amir, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102084 · Cited by 120
Cortiula, F., Reymen, B. J. T., Peters, S., Mol, P. V., Wauters, E., Vansteenkiste, J., Ruysscher, D. D., & Hendriks, L. E. L. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.013 · Cited by 105
Fukui, T., Okuma, Y., Nakahara, Y., Otani, S., Igawa, S., Katagiri, M., Mitsufuji, H., Kubota, M., Hiyoshi, Y., Ishihara, M., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.021 · Cited by 105
Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
Verdura, S., Cuyàs, E., Martin-Castillo, B., & Menendez, J. A. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1633235 · Cited by 98
Shi, Y. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900215 · Cited by 100
Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives
Rozeman, E. A., Dekker, T. J. A., Haanen, J. B. A. G., & Blank, C. U. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0325-6 · Cited by 109
Molecular landscape of esophageal cancer: implications for early detection and personalized therapy
Talukdar, F. R., di Pietro, M., Secrier, M., Moehler, M. H., Goepfert, K., Soares‐Lima, S. C., Pinto, L. F. R., Hendricks, D. T., Parker, M. I., & Herceg, Z. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13876 · Cited by 104
Wu, J., Liu, C., Liu, X., Sun, W., Li, L., Gao, N., Zhang, Y., Yang, X., Zhang, J., Wang, H., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00904-9 · Cited by 109
The Cancer Immunotherapy Biomarker Testing Landscape
Walk, E. E., Yohe, S. L., Beckman, A., Schade, A. E., Zutter, M. M., Pfeifer, J. D., & Berry, A. B. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0584-cp · Cited by 107
Immunoscore and its introduction in clinical practice
Galon, J., & Lanzi, A. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03249-5 · Cited by 104
PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy
Rolfes, V., Idel, C., Pries, R., Plötze‐Martin, K., Habermann, J. K., Gemoll, T., Bohnet, S., Latz, E., Ribbat‐Idel, J., Franklin, B. S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25446 · Cited by 101
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 94
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Mehnert, J. M., Monjazeb, A. M., Beerthuijzen, J. M. T., Collyar, D., Rubinstein, L., & Harris, L. N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3063 · Cited by 92
Kirsch, D. G., Diehn, M., Kesarwala, A. H., Maity, A. M., Morgan, M. A., Schwarz, J. K., Bristow, R. G., Demaria, S., Eke, I., Griffin, R. J., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx231 · Cited by 102
PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
Xu, Y., Gao, Z., Hu, R., Wang, Y., Wang, Y., Su, Z., Zhang, X., Yang, J., Mei, M., Ren, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002699 · Cited by 102
Mari, L., Hoefnagel, S. J. M., Zito, D., van de Meent, M., van Endert, P., Calpe, S., Sancho Serra, M. D. C., Heemskerk, M. H. M., van Laarhoven, H. W. M., Hulshof, M. C. C. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.030 · Cited by 89
Immunological effects of BRAF+MEK inhibition
Ascierto, P. A., & Dummer, R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1468955 · Cited by 88
Bridge, J. A., Lee, J., DAUD, A. I., Wells, J. W., & Bluestone, J. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00351 · Cited by 89
Current status and perspectives in immunotherapy for metastatic melanoma
Marconcini, R., (IMI), F. T. I. M. I., Spagnolo, F., Stucci, L. S., Ribero, S., Marra, E., Rosa, F. D., Picasso, V., Guardo, L. D., Cimminiello, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23746 · Cited by 90
Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma
Suo, A., Chan, Y., Beaulieu, C., Kong, S., Cheung, W. Y., Monzon, J. G., Smylie, M., Walker, J., Morris, D., & Cheng, T. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0674 · Cited by 83
Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy
Loo, K. L., Tsai, K. K., Mahuron, K. M., Liu, J., Pauli, M. L., Sandoval, P. M., Nosrati, A., Lee, J., Chen, L., Hwang, J. J., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93433 · Cited by 86
Khoja, L., Atenafu, E. G., Templeton, A. J., Qye, Y., Chappell, M. A., Saibil, S. D., Hogg, D., Butler, M. O., & Joshua, A. M. (2016) · Cancer Medicine · doi:10.1002/cam4.878 · Cited by 82
Implementing liquid biopsies into clinical decision making for cancer immunotherapy
Quandt, D., Zucht, H. D., Amann, A., Wulf-Goldenberg, A., Borrebaeck, C. A. K., Cannarile, M. A., Lambrechts, D., Oberacher, H., Garrett, J., Nayak, T. K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17397 · Cited by 88
Interlaboratory concordance of PD‐L1 immunohistochemistry for non‐small‐cell lung cancer
Scheel, A. H., Baenfer, G., Baretton, G., Dietel, M., Diezko, R., Henkel, T., Heukamp, L. C., Jasani, B., Jöhrens, K., Kirchner, T., et al. (2018) · Histopathology · doi:10.1111/his.13375 · Cited by 80
Tarhini, A. A., & Kudchadkar, R. R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.005 · Cited by 87
Biomarkers of response to immune checkpoint blockade in cancer treatment
Fujii, T., Naing, A., Rolfo, C. D., & Hajjar, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.010 · Cited by 81
Fässler, M., Diem, S., Mangana, J., Ali, O. H., Berner, F., Bomze, D., Ring, S. S., Niederer, R., Gil‐Cruz, C., Perez‐Shibayama, C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0523-2 · Cited by 81
D’Anna, F., Dyck, L. V., Xiong, J., Zhao, H., Berrens, R. V., Qian, J., Bieniasz-Krzywiec, P., Chandra, V., Schoonjans, L., Matthews, J. B., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02087-z · Cited by 78
Pellegrino, B., Musolino, A., Llop‐Guevara, A., Serra, V., Silva, P. D., Hlavata, Z., Sangiolo, D., Willard-Gallo, K. E., & Solinas, C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.10.010 · Cited by 82
High-dimensional role of AI and machine learning in cancer research
Capobianco, E. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01689-z · Cited by 98
A user's perspective on GeoMxTM digital spatial profiling
Van, T. M., & Blank, C. U. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.05.001 · Cited by 73
Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy
Gu, Y., Zhang, Z., & ten Dijke, P. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-00980-8 · Cited by 80
Montagna, G., Gupta, H. V., Hannum, M., Tan, K. S., Lee, J., Scarpa, J. R., Plitas, G., Irie, T., McCormick, P. J., Fischer, G. W., et al. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.10.021 · Cited by 79
Stecher, C., Battin, C., Leitner, J. M., Zettl, M., Grabmeier‐Pfistershammer, K., Höeller, C., Zlabinger, G. J., & Steinberger, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00572 · Cited by 77
Hu‐Lieskovan, S., Lisberg, A. E., Zaretsky, J. M., Grogan, T., Rizvi, H. A., Wells, D. K., Carroll, J., Cummings, A. L., Madrigal, J., Jones, B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4275 · Cited by 77
Actors on the Scene: Immune Cells in the Myeloma Niche
Leone, P., Solimando, A. G., Malerba, E., Fasano, R., Buonavoglia, A., Pappagallo, F., Re, V. D., Argentiero, A., Silvestris, N., Vacca, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.599098 · Cited by 76
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review
Larroquette, M., Domblides, C., Lefort, F., Lasserre, M., Quivy, A., Sionneau, B., Bertolaso, P., Gross‐Goupil, M., Ravaud, A., & Daste, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.013 · Cited by 87
Wong, A. N. M., Callahan, J., Keyaerts, M., Neyns, B., Mangana, J., Aberle, S., Herschtal, A., Fullerton, S., Milne, D., Iravani, A., et al. (2020) · Cancer Imaging · doi:10.1186/s40644-020-00313-2 · Cited by 78
Neoantigens encoded in the cancer genome
Schumacher, T. N., & Hacohen, N. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.07.005 · Cited by 80
Targeting tumor-associated acidity in cancer immunotherapy
Lacroix, R., Rozeman, E. A., Kreutz, M. P., Renner, K., & Blank, C. U. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2195-z · Cited by 77
Fukuda, S., Saito, K., Yasuda, Y., Kijima, T., Yoshida, S., Yokoyama, M., Ishioka, J., Matsuoka, Y., Kageyama, Y., & Fujii, Y. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001564 · Cited by 71
Garg, A. D., Vandenberk, L., Van Woensel, M., Belmans, J., Schaaf, M., Boon, L., De Vleeschouwer, S., & Agostinis, P. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1295903 · Cited by 71
Chat, V., Ferguson, R., Simpson, D., Kazlow, E., Lax, R., Moran, U., Pavlick, A. C., Frederick, D. T., Boland, G. M., Sullivan, R. J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02318-8 · Cited by 87
Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
Das, A., Tabori, U. Y., Nahum, L. C. S., Collins, N. B., Deyell, R. J., Dvir, R., Faure‐Conter, C., Hassall, T., Minturn, J. E., Edwards, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0411 · Cited by 74
Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy
Yang, M., Zhou, J., Lu, L., Deng, D., Huang, J., Tang, Z., Shi, X., Lo, P., Lovell, J. F., Zheng, Y., et al. (2024) · Exploration · doi:10.1002/exp.20230171 · Cited by 89
Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival
Wiencke, J. K., Koestler, D. C., Salas, L. A., Wiemels, J. L., Roy, R., Hansen, H. M., Rice, T., Mccoy, L. S., Bracci, P. M., Molinaro, A. M., et al. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0316-8 · Cited by 75
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
Zemek, R. M., Chin, W. L., Nowak, A. K., Millward, M., Lake, R., & Lesterhuis, W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00223 · Cited by 75
Comprehensive analysis of cutaneous and uveal melanoma liver metastases
Hoefsmit, E. P., Rozeman, E. A., Van, T. M., Dimitriadis, P., Krijgsman, O., Conway, J. W., da Silva, I. P., van der Wal, J. E., Ketelaars, S. L. C., Bresser, K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001501 · Cited by 74
Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL
Hohtari, H. R., Brück, O. E., Blom, S., Turkki, R., Sinisalo, M., Kovanen, P. E., Kallioniemi, O., Pellinen, T. S., Porkka, K., & Mustjoki, S. M. (2019) · Leukemia · doi:10.1038/s41375-018-0360-1 · Cited by 74
Gopal, A. K., Levy, R., Houot, R., Patel, S. P., Popplewell, L. L., Jacobson, C. A., Mu, X. J., Deng, S., Ching, K. A., Chen, Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2973 · Cited by 69
Kato, S., Okamura, R., Kumaki, Y., Ikeda, S., Nikanjam, M., Eskander, R. N., Goodman, A. M., Lee, S., Glenn, S. T., Dressman, D. C., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1708065 · Cited by 70
Wang, X., Collet, L., Rediti, M., Debien, V., Caluwé, A. D., Venet, D., Romano, E., Rothé, F., Sotiriou, C. P., & Buisseret, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030953 · Cited by 76
Kümpers, C., Jokić, M., Haase, O., Offermann, A., Vogel, W., Grätz, V., Langan, E. A., Perner, S., & Terheyden, P. A. M. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00027 · Cited by 65
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
Vos, J. L., Burman, B., Jain, S., Fitzgerald, C. W. R., Sherman, E. J., Dunn, L. A., Fetten, J. V., Michel, L. S., Kriplani, A., Ng, K., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02518-x · Cited by 68
Tolba, M. F. (2020) · International Journal of Cancer · doi:10.1002/ijc.33056 · Cited by 73
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
Lhuillier, C., Vanpouille-Box, C., Galluzzi, L., Formenti, S. C., & Demaria, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.007 · Cited by 62
Zoumpourlis, P., Genovese, G., Tannir, N. M., & Msaouel, P. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.11.005 · Cited by 66
Omori, M., Okuma, Y., Hakozaki, T., & Hosomi, Y. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1765 · Cited by 66
Recent advances in understanding antitumor immunity
Munhoz, R. R., & Postow, M. A. (2016) · F1000Research · doi:10.12688/f1000research.9356.1 · Cited by 84
Kim, K., Kim, H. S., Kim, J. Y., Jung, H., Sun, J., Ahn, J. S., Ahn, M., Park, K., Lee, S., & Choi, J. K. (2020) · Nature Communications · doi:10.1038/s41467-020-14562-z · Cited by 67
Janikovits, J., Müller, M., Krzykalla, J., Körner, S., Echterdiek, F., Lahrmann, B., Grabe, N., Schneider, M. A., Benner, A., Doeberitz, M. V. K., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1390640 · Cited by 65
Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
Filipović, A., Miller, G., & Bolen, J. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00155 · Cited by 64
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Denis, M., Duruisseaux, M., Brevet, M., & Dumontet, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00492 · Cited by 65
Immune Checkpoint Inhibitors in the Management of Lung Cancer
Zimmermann, S., Peters, S., Owinokoko, T., & Gadgeel, S. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201319 · Cited by 62
DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers
Bañobre, J. R., & Goel, A. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.11.071 · Cited by 62
Integrating the Tumor Microenvironment into Cancer Therapy
Sanegre, S., Lucantoni, F., Burgos‐Panadero, R., de la Cruz‐Merino, L., Noguera, R., & Naranjo, T. Á. (2020) · Cancers · doi:10.3390/cancers12061677 · Cited by 61
Dong, Z., Zhang, C., Li, Y., Su, J., Xie, Z., Liu, S. M., Yan, L., Chen, Z., Yang, X., Lin, J., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.020 · Cited by 66
Wiesweg, M., Mairinger, F. D., Reis, H., Goetz, M., Kollmeier, J., Misch, D., Stephan-Falkenau, S., Mairinger, T., Walter, R. F. H., Hager, T., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.015 · Cited by 60
Yang, C., Cui, M., Zhang, Y., Pan, H., Liu, J., Wang, S., Ma, N., Chang, J. K., Sun, T., & Wang, H. (2020) · Communications Biology · doi:10.1038/s42003-020-01287-4 · Cited by 60
Breast cancer vaccines: Heeding the lessons of the past to guide a path forward
Solinas, C., Aiello, M. M., Migliori, E., Willard-Gallo, K. E., & Emens, L. A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101947 · Cited by 57
Xu, J., Saklatvala, R., Mittal, S., Deshmukh, S., & Procopio, A. (2020) · Advanced Science · doi:10.1002/advs.201903394 · Cited by 56
Bravaccini, S., Bronte, G., & Ulivi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126536 · Cited by 64
Estrogens, Cancer and Immunity
Orzołek, I., Sobieraj, J., & Domagala-Kulawik, J. J. (2022) · Cancers · doi:10.3390/cancers14092265 · Cited by 65
Scientific Advances in Thoracic Oncology 2016
Soo, R. A., Stone, E. C. A., Cummings, K. M., Jett, J. R., Field, J. K., Groen, H. J. M., Mulshine, J. L., Yatabe, Y., Bubendorf, L., Đačić, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.019 · Cited by 56
Surface Oncology, 5. H. S., Rausch, M. P., & Hastings, K. T. (2017) · Codon Publications eBooks · doi:10.15586/codon.cutaneousmelanoma.2017.ch9 · Cited by 75
Immune biological rationales for the design of combined radio- and immunotherapies
Hader, M., Frey, B., Fietkau, R., Hecht, M., & Gaipl, U. S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02460-3 · Cited by 60
Quinn, C., Garrison, L. P., Pownell, A. K., Atkins, M. B., de Pouvourville, G., Harrington, K. J., Ascierto, P. A., McEwan, P. C., Wagner, S., Borrill, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000648 · Cited by 55
Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors
Bossi, P., Ascierto, P. A., Basset‐Séguin, N., Dréno, B., Dummer, R., Hauschild, A., Mohr, P., Kaufmann, R., Pellacani, G., Puig, S., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104066 · Cited by 56
The innate immune architecture of lung tumors and its implication in disease progression
Milette, S., Fiset, P., Walsh, L. A., Spicer, J. D., & Quail, D. F. (2019) · The Journal of Pathology · doi:10.1002/path.5241 · Cited by 58
Saulīte, I., Ignatova, D., Chang, Y., Fassnacht, C., Dimitriou, F., Varypataki, E. M., Anzengruber, F., Nägeli, M., Cozzio, A., Dummer, R., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1738797 · Cited by 54
Kaptein, P., Jacoberger-Foissac, C., Dimitriadis, P., Voabil, P., de Bruijn, M., Brokamp, S., Reijers, I., Versluis, J., Nallan, G., Triscott, H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9779 · Cited by 52
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
Cao, J., Brouwer, N. J., Richards, K., Marinkovic, M., van Duinen, S. G., Hurkmans, D. P., Verdegaal, E. M. E., Jordanova, E. S., & Jager, M. J. (2017) · Oncotarget · doi:10.18632/oncotarget.18039 · Cited by 54
Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy
Lee, E. S., Shin, J. M., Son, S., Ko, H., Um, W., Song, S. H., Lee, J. A., & Park, J. H. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801320 · Cited by 54
Kobayashi, Y., Kushihara, Y., Saito, N., Yamaguchi, S., & Kakimi, K. (2020) · Cancer Science · doi:10.1111/cas.14621 · Cited by 60
High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions
Blaha, D. T., Anderson, S. D., Yoakum, D. M., Hager, M. V., Zha, Y., Gajewski, T. F., & Kranz, D. M. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0395 · Cited by 49
Going to extremes: determinants of extraordinary response and survival in patients with cancer
Saner, F. A. M., Herschtal, A., Nelson, B. H., deFazio, A., Goode, E. L., Ramus, S. J., Pandey, A., Beach, J. A., Fereday, S., Berchuck, A., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0145-5 · Cited by 51
Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
Gjoerup, O. V., Brown, C. A., Ross, J. S., Huang, R. S. P., Schrock, A. B., Creeden, J., Fabrizio, D. A., & Tolba, K. A. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00514-4 · Cited by 55
Metadata
- Authors
- Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of California, Los Angeles (US)
- Venue
- Science
- Published
- 2016-05-06
- Volume
- 352
- Issue
- 6286
- Pages
- 658-660
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2346108121
- Cited by
- 748
- References
- 36
- Citations by year
- 2026: 23 · 2025: 37 · 2024: 54 · 2023: 61 · 2022: 66 · 2021: 92 · 2020: 113 · 2019: 78 · 2018: 104 · 2017: 94 · 2016: 23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-immune interactions, tumor immune microenvironment, immune checkpoint inhibitors, precision oncology, immune profiling
- MeSH terms
- Animals, Humans, Immunotherapy, Macrophages, Neoplasms, T-Lymphocytes, Biomarkers, Tumor, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Mice, Precision Medicine, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.